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Available online at www.sciencedirect.comThe major neurodegenerative diseases are characterised by a
disabling loss of the daily pattern of sleep and wakefulness,
which may be reflective of a compromise to the underlying
circadian clock that times the sleep cycle. At a molecular level,
the canonical property of neurodegenerative diseases is
aberrant aggregation of otherwise soluble neuronal proteins.
They can thus be viewed as disturbances of proteostasis,
raising the question whether the two features — altered daily
rhythms and molecular aggregation — are related. Recent
discoveries have highlighted the fundamental contribution of
circadian clocks to the correct ordering of daily cellular
metabolic cycles, imposing on peripheral organs such as the
liver a strict programme that alternates between anabolic and
catabolic states. The discovery that circadian mechanisms are
active in local brain regions suggests that they may impinge
upon physiological and pathological elements that influence
pro-neurodegenerative aggregation. This review explores how
introducing the dimension of circadian time and the circadian
clock might refine the analysis of aberrant aggregation, thus
expanding our perspective on the cell biology common to
neurodegenerative diseases.
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Introduction
The prevalence of neurodegenerative diseases is growing
relentlessly as the population ages. Regardless of their
origin, these diseases are characterised by the aberrant
aggregation of otherwise soluble proteins. In the case of
Open access under CC BY license.Current Opinion in Neurobiology 2013, 23:880–887 Alzheimer’s disease (AD) these are extracellular plaques
of Ab and intracellular filaments of the microtubule-
associated protein tau, whilst a-synuclein deposits typify
Lewy pathology disorders, including Parkinson’s disease
(PD). Huntington’s disease (HD) is caused by huntingtin
protein carrying an expanded number of CAG repeats,
whilst tauopathy, synucleinopathy and expanded tri-
nucleotide-repeats are also associated with other neuro-
degenerative diseases. The specific brain and spinal cord
regions affected lead to the characteristic clinical mani-
festations [1].
One feature common to many neurodegenerative dis-
eases is acceleration of the age-related disruption of
the daily cycle of sleep and wakefulness [2–5]. This is
evidenced both clinically and in animal models of disease
(Figure 1) [6], and, because of the consequent disturb-
ance of the sleep pattern of carers [7,8], is the principal
reason for institutionalization of patients, with the attend-
ant personal, economic and social costs. It is not yet clear
whether these sleep disturbances arise from a defect in
the core mechanisms that govern the timing of sleep and
wakefulness (the suprachiasmatic nucleus or SCN), the
nuclei that promote states of sleep (e.g. ventro-lateral pre-
optic area (VLPO)) and wakefulness (e.g. tubero-mam-
millary nucleus (TMN) and locus coeruleus) or an
inability of the diseased brain to sustain consolidated
bouts of sleep and wakefulness, even though the timing
pathways may be fully functional. For example, overall
neurodegeneration within the SCN is seen in AD, and
intriguingly the loss of different cell types within the
SCN: arginine vasopressin (AVP) or neurotensin cells, is
associated with differential effects, respectively, on
activity rhythm fragmentation or activity (and tempera-
ture) rhythm amplitude [9]. On the other hand, neuro-
degenerative pathologies have also been observed in
sleep-regulatory centres [7,10]. The pathobiological pro-
cess resulting in AD may begin with mis-folded and
abnormally hyper-phosphorylated tau protein located in
the proximal axon of noradrenergic locus coeruleus pro-
jection neurons [11]. Subsequently, similar material fills
the somato-dendritic compartment of these cells, result-
ing in their likely dysfunction. In separate experiments, it
has been shown that the optogenetic activation of locus
coeruleus neurons rapidly awoke mice that were asleep
[12]. The prodrome of PD and dementia with Lewy
bodies, which is characterised by neuropathological
changes that precede parkinsonism and dementia,
includes rapid eye movement (REM) sleep behaviour
disorder, a parasomnia with dream-enacting behaviour,www.sciencedirect.com
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Daily cycles of rest, sleep and activity are disturbed in human neurodegenerative diseases and animal models thereof. Double-plotted actograms in
humans and wheel-running behaviour in mice reveal stable behavioural patterns in unaffected individuals (a, d), but severe disturbances in Alzheimer’s
disease and Huntington’s disease (b, c), the R6/2 mouse model of Huntington’s disease (e) and a mouse lacking the circadian genes mPer1 and
mPer2 (f). (a, b) from [3], (c) from [70], (d, e) from [6] and (f) unpublished from one of the authors (MHH).and loss of REM sleep atonia [13,14]. Lewy pathology is
abundant in the lower brainstem, with only minimal
damage in the substantia nigra [15]. Because of the
intimate relationship between circadian timing and sleep,
and the widespread distribution of neuropathology, it is
difficult, therefore, to disentangle cause and effect. For
example, in the R6/2 mouse model of HD, circadian gene
expression in the SCN was compromised in vivo, but
when SCN tissue was cultured, circadian pacemaking was
normal, suggesting that the dysfunction in the SCN was
secondary to changes elsewhere in the brain [16].
Available evidence does not, therefore, allow identifi-
cation of a single point of action or mechanism of effect
to explain disordered sleep/wake patterns in neurodegen-
erative diseases. These observations have nevertheless
spurred attempts to manage these diseases by applying a
strict daily programme to impose more ordered sleep
cycles upon patients and experimental mouse models.
To date, these have met with mixed success. In a mouse
model of HD, imposition of a more stable daily activity
cycle by either pharmacological [16] or behavioural means
[17] improved cognitive and metabolic functions, whereas
daily treatment with melatonin and bright light had only a
modest beneficial effect on cognitive function in institu-
tionalized patients [18]. Regular bright light therapy can
also alleviate depressive symptoms in elderly patients,
and so may be a general pick-me-up [19]. At best, such
approaches offer symptomatic relief.www.sciencedirect.com The aim of this Opinion piece, therefore, is to consider
the broader perspective provided by the latest develop-
ments in the cell biology of circadian clocks and neuro-
degenerative diseases. Regardless of clinical
manifestations, the signature feature of disease is abnor-
mal protein aggregation. The fundamental issue, therefore, is
the extent to which the circadian axis might impinge upon
cellular pathology. Importantly, this is the reverse of con-
ventional approaches that have focused upon what neu-
rodegeneration might do to circadian function.
Circadian clocks co-ordinate cell biology in
time
The detailed molecular genetics of circadian pacemaking
are covered elsewhere (Hardin, this issue). In summary,
the mammalian clock consists of a delayed feedback loop
in which the circadian clock genes Per and Cry are
negatively regulated by their cognate protein products
on a daily basis (Figure 2a). This mechanism is recapi-
tulated in most, if not all, cells and is understood at atomic
resolution [20,21]. By virtue of its innervation by the
retina, the interneuronal signalling that maintains its
circuit-level pacemaking and its efferent connections,
the SCN is the principal pacemaker. Importantly, other
brain regions and peripheral tissues also contain local
circadian clocks (Figure 2b) and the critical function of
the SCN is that, via its regulation of neural, behavioural
and endocrine outputs, it maintains circadian order across
brain and body (Menaker, this issue). The importance ofCurrent Opinion in Neurobiology 2013, 23:880–887
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The circadian clock mechanism in mammals: a negative feedback
oscillator distributed widely across the brain. (a) Schematic
representation of the core negative feedback loop. Heterodimeric Clock/
Bmal1 complexes transactivate Period and Cryptochrome during early
circadian day via E-box regulatory sequences. Following translation and
nuclear localisation of their own protein products, this leads to negative
regulation of these genes during early circadian night. Subsequent
degradation of Per and Cry during the night releases negative regulation
and transactivation can start again, defining a new circadian day. Many
downstream, clock-controlled genes also carry E-boxes and so are
subject to alternate phases of activation and repression across the
circadian cycle, thereby directing daily cascades of cellular function. (b)
Distributed circadian clocks across the mammalian brain.
Bioluminescence recordings from organotypic brain slice cultures
derived from mPER2:LUC reporter mice demonstrate autonomous
circadian molecular cycles, not only in the principal pacemaker of the
SCN, but also in other brain regions. In vivo, these distributed clocks
would be synchronised to the SCN pacemaker.this order is that it establishes daily rhythms of metab-
olism and behaviour that adapt the individual to the day–
night cycle and that it segregates incompatible bio-
chemical processes in time. At the level of sleep, it is a
given that effective sleep requires absolute synchrony
between distributed clocks in the brain. Sleep and wake-
fulness are integrated, global states across the central
nervous system that would be compromised by temporal
disorder between different regions. The SCN clock syn-
chronises local brain clocks to maintain this order.Current Opinion in Neurobiology 2013, 23:880–887 Evidence of the deep nature of circadian temporal pro-
gramming is provided by transcriptomic [22,23] and
proteomic analyses [24,25] of liver, SCN and other
tissues, which have shown that 5–10% of a local tran-
scriptome is clock-regulated. In neurons, such a circadian
programme, controlled by local clocks, will regulate
synaptic, trophic and other processes, leading to systema-
tic changes in the function of the neuron coincident with
the SCN-determined cycle of wakefulness and sleep.
Moreover, these local programmes are subject to altera-
tion by sleep deprivation (Cirelli, this issue). The import-
ant point is that the cell biology of neurodegenerative
aggregation very likely proceeds in the context of circa-
dian modulation of some, perhaps many, of the key
processes within the affected neuron and its surround-
ings. Although there has been some basic success in
analysing the role of clock genes in sleep (Franken, this
issue), compelling evidence for a contribution of clock
gene dysfunction to neurodegenerative diseases and
sleep disorders is lacking [26–28]. To explore this further,
therefore, it is necessary to map out the generic events
driving aggregation and to identify likely mechanisms for
their circadian modulation. Are there circadian clock-de-
pendent checkpoints in the mechanisms of neurodegen-
erative aggregation that might provide novel routes to
therapy?
The canonical signature of neurodegeneration
is protein aggregation
Proof of the causative role of particular proteins in AD,
PD, HD and other neurodegenerative diseases is pro-
vided by familial cases of disease that carry dominantly
inherited mutations in the relevant genes [1]. Typically,
the mis-folded proteins form highly ordered filamentous
inclusions with a core region of cross-b-conformation.
With the exception of HD and other tri-nucleotide repeat
diseases, most cases of neurodegenerative disease occur
in the absence of causative mutations, with protein mis-
folding arising from stochastic, environmental and likely
multigenic causes. This raises the question of how it is
that the wild-type versions of these otherwise soluble
proteins start to aggregate and kill neurons? Recent
studies highlight major areas of interest (outlined in lower
part of Figure 3), the first being the identity of the toxic
factor(s). The progressive accumulation of large aggre-
gates points inevitably to their causal involvement. An
alternative view, however, is that toxicity arises from
soluble intermediates or oligomeric forms, and that the
end-point aggregates simply represent the nervous sys-
tem’s attempts to sequester proteins it is unable to dis-
pose of by standard proteasomal and autophagic routes.
Indeed, perhaps compromised function of the protea-
some and autophagy arising from such intermediates
may be the principal toxic insult to the cell (see below).
In addition, there may be interactions between patho-
genic proteins. For example, tau protein may be an arbiter
of the pathological effects of Ab in AD [29]. The origin ofwww.sciencedirect.com
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Circadian influences on neurodegenerative protein aggregation. Schematic model to highlight possible intersections between the circadian clock and
mechanisms underpinning neurodegenerative protein aggregation. The life-history of benign cytosolic proteins is mapped in green as a series
incorporating gene expression, folding, post-translational modifications (here represented by phosphorylation), oxidation and, ultimately, clearance
through proteasomal degradation and autophagy. Pro-neurodegenerative mechanisms have been identified at every stage, leading to the aggregation
of otherwise soluble proteins and their spreading through prion-like mechanisms. The origins of neurotoxicity are unclear, but presumably involve a
gain of toxic function. Significantly, many, if not most, of these physiological and pro-neurodegenerative mechanisms are under circadian regulation.
Thus, in addition to neurodegenerative diseases affecting the circadian clock, the circadian clock has the potential to promote (or hinder) disease
progression.toxicity, however, is unclear, although possibilities in-
clude disordered synaptic signalling and disruption of
particular organelles, for example mitochondria (see
below).
But how might mis-folding occur and propagate in the
first place? Recent attention has focused on the putative
prion-like behaviour of abnormal protein aggregates.
Until recently, aggregation was thought to be a cell-
autonomous process, with aggregates forming indepen-
dently in neurons and glia, and this may well be the case
for the mutant proteins in familial cases. A series of recent
studies has shown, however, that when aggregates were
injected into the brains of recipient animals, they trig-
gered aggregation of the cognate soluble protein in the
host [1]. Significantly, in the case of tau, immunodeple-
tion of the protein before injection prevented trans-
mission, indicative of tau-mediated intercellular
propagation of [30]. Similarly, the form of amyloid-b,www.sciencedirect.com can exhibit prion-like seeding of neurodegeneration in
mouse brain that is dependent upon tau [31]. In the
clinical context of PD, a-synuclein-containing Lewy
body pathology has been reported to be transmitted from
the brains of patients into the foetal dopaminergic grafts
they received as therapy [32–34]. A view is developing,
therefore, that just as mis-folded prion protein is able to
convert normal soluble protein to the mis-folded state,
then so might neurodegenerative aggregates also spread
by intercellular transmission.
The third point of interest is the potential contribution to
neurodegeneration from reactive oxygen species (ROS)
within a cell, and how they may trigger mis-handling of
wild-type protein. Failure to control the oxidation state of
proteins can arise from mitochondrial disease and com-
promised antioxidant function. Most directly, mutations
of the antioxidant superoxide dismutase 1 (SOD1) cause
amyotrophic lateral sclerosis (ALS), although this mayCurrent Opinion in Neurobiology 2013, 23:880–887
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Nevertheless, more general associations have been drawn
between proteins implicated in familial neurodegenera-
tive diseases, including Parkin and a-synuclein, and
mitochondrial function [35]. The two lines of potential
causality: ROS causes mis-folding and aggregation, and
aggregate or soluble proteins impair the ability of the cell
to handle ROS, have yet to be disentangled.
A final emerging theme is that of autophagy. Under normal
circumstances autophagosomes accumulate unwanted,
damaged proteins and organelles and on merging with
lysosomes, degrade them for export or re-cycling. Com-
promise of autophagy will aggravate ROS production by
damaged mitochondria, and when induced by pharmaco-
logical or genetic means, aggravate the neurodegenerative
condition in cell-based and animal models [36]. On the
other hand, facilitation of autophagy can attenuate protein
aggregation and neurodegeneration [37]. A more complex
interplay between autophagy and neurodegeneration,
however, has been revealed by the demonstration that
both soluble and aggregated a-synucleins impair autop-
hagy [38,39], again raising questions of cause and effect. If
it is the general case that specific aggregate-prone proteins
can disrupt the proteostasis of the entire cell [40], then the
circadian clock, via its widespread influence upon the
proteome [24], may well be able to aggravate or attenuate
aggregation-induced autophagy and susceptibility to mito-
chondrial dysfunction and cellular apoptosis.
Where might clock-relevant processes
intervene in protein aggregation and its
consequences?
The pervasive influence of the circadian system on normal
proteostasis and pro-neurodegenerative processes is out-
lined in Figure 3. The most immediate way for the clock to
influence neurodegeneration is by circadian control over
the expression of pro-neurodegenerative factors. This has
been reported for several relevant genes in various rodent
tissues [41,42]. For example, presenilin-2, which regulates
the cleavage of amyloid precursor protein (APP), is a direct
target of CLOCK/BMAL1 transcriptional regulation, and
is expressed with a strong circadian rhythm. TDP-43 is the
principal pathogenic protein in tau-negative fronto-
temporal dementia (FTLD-TDP) and in many forms of
ALS, and at the transcript level is very highly circadian in
mouse brain, as well as in liver and kidney. Similarly, a-
synuclein and g-synuclein are rhythmic in various tissues
and the synuclein-interacting protein synphilin shows a
strong circadian cycle in brain. This may be of direct
relevance for disease, since the overexpression of wild-
type a-synuclein can give rise to PD and dementia with
Lewy bodies [43–45]. Genome-wide association studies
have established that modest overexpression of a-synu-
clein may be a risk factor for idiopathic PD [46,47]. The
same may also be true of multiple system atrophy (MSA),
another synucleinopathy [48]. Similarly, mutations in FUSCurrent Opinion in Neurobiology 2013, 23:880–887 are associated with forms of FTD and ALS and again this
gene is expressed with a very strong circadian rhythm in
adrenal gland, liver and brain. At a transcriptional level,
therefore, clock mechanisms may contribute to pro-neu-
rodegenerative processes by elevating expression levels of
the naturally occurring form of the protein on a recurrent
daily basis, incurring progressive risk throughout the life-
span.
At the protein level, a healthy cell will progress through a
daily cycle of alternating metabolic states directed by the
circadian system, with proteins synthesised and degraded
and organelles remodelled to sustain time-dependent
cellular activities. Both the proteasomal and autophago-
cytic pathways play pivotal roles in this, releasing nutri-
ents for re-cycling during periods of fasting and removing
damaged or unnecessary organelles. In the liver and other
tissues in vivo and in primary hepatocytes in vitro, this
timely progression is underpinned by the circadian con-
trol of autophagy [49,50]. Pivotal to this temporal control
in the liver is circadian expression of the transcription
factor C/EBPb that in turn directs the circadian expres-
sion of a range of autophagy genes. It is not clear whether
a comparable pathway exists in neurons, although prima
facie there is no reason to believe something similar is not
expressed, given the widespread incidence of autophagy
rhythms in peripheral tissues and the expression of var-
ious C/EBP family members in the brain. Circadian
modulation of autophagocytic capacity would establish
particular phases of day or night when the neurons are
more susceptible to aggregation and mitochondrial dys-
function, and potentially this would be exacerbated by
circadian and/or sleep disturbance which would reduce
the daily peak capacity for autophagy. In a similar vein,
there is tight, reciprocal interplay between the circadian
clock and the proteasomal machinery. First, genetic [51]
or pharmacological [52] manipulations that compromise
ubiquitination and proteasomal degradation of clock
proteins impede the timely progress of the feedback
loops, slowing the pacemaker and its dependent meta-
bolic rhythms. Second, in the liver, a significant number
of genes coding for chaperonins and elements of the
ubiquitin/proteasome pathway are under circadian regu-
lation (F box-containing proteins, ubiquitin-like proteins,
ubiquitin-conjugating enzymes, ubiquitin fusion degra-
dation-like proteins and proteasomal subunits) [23]. As
with autophagy, the capacity of cells to quality-control,
degrade and clear unwanted proteins varies across the
circadian cycle, thereby limiting the ability of the cell to
deal with mis-folded monomers, toxic intermediates and
aggregates alike. Disturbance of this circadian pro-
gramme in neurons would enhance their susceptibility
to a pre-existing neurodegenerative state.
A significant source of damage to pro-neurodegenerative
proteins arises from oxidative stress, and circadian
influences on the redox state of a cell are manifest inwww.sciencedirect.com
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pathways, transcriptomic [22,23] and proteomic
analyses [24,25] have shown that the expression of
oxidative metabolic enzymes and antioxidant factors is
modulated by the circadian system in both liver and
brain. The ability of cells to deal with the consequences
of dysfunctional mitochondria is therefore clock-gated.
Mice deficient in the transcription factor BMAL1,  an
essential component of the mammalian clock, have
reduced lifespans and display signs of premature aging
in some non-neuronal tissues [53]. The phenotype of
premature aging correlated with increased levels of reac-
tive oxygen species. It will be interesting to see what
happens in the brain of these animals and what effect the
lack of BMAL1 has in existing models of human neuro-
degenerative diseases. Of course, the deficits may not be
exclusively clock-dependent, insofar as BMAL1 may act
in a non-circadian manner. Nevertheless, circadian
disturbance from other sources may have an impact upon
BMAL1 expression in its role as a clock component, and
thereby affect its non-circadian actions. A second aspect
arises from recent studies of circadian redox rhythms,
evidenced by superoxidation of peroxiredoxins. In liver,
these ubiquitous antioxidant proteins show high ampli-
tude circadian cycles of transcription, protein abundance
and post-translational modification [24,25]. Astonish-
ingly, and counter to the transcriptional feedback loop
model of the mammalian clock, circadian rhythms of
post-translational  superoxidation persist in anucleate
erythrocytes, incapable of transcription. Comparable
rhythms are also evident in peripheral tissues and in
brain [54] and appear to be an ancient and deeply
embedded feature of eukaryotic cells. The rhythm of
superoxidation is a clear demonstration of circadian vari-
ation of the redox state of cells, and it has obvious
implications for the progress of pro-neurodegenerative
protein damage.
An additional post-translational modification implicated
in neurodegeneration is phosphorylation, which can
vary between soluble and aggregated states. Daily
changes in the phosphorylation of circadian proteins
are tightly regulated in order to control properties such
as intracellular localisation, oligomerisation and degra-
dation and prima facie similar programmes may be
anticipated for at least some of the proteins that are
prone to mis-folding in neurodegeneration. The abnor-
mal hyper-phosphorylation of tau is an early and invar-
iant feature of human tauopathies. Its increased
phosphorylation is not necessarily detrimental, since
it occurs reversibly during foetal brain development,
hibernation and hypothermia [55–58]. The effect of
hypothermia is the result of an exponential decrease
in the activity of protein phosphatase 2A (PP2A), the
major tau phosphatase in brain, and also a clock-relevant
phosphatase [59] expressed with a circadian rhythm in
SCN [41]. Reductions in both PP2A expression andwww.sciencedirect.com activity have been reported in AD brain [60,61].
Although it remains to be seen if different mechanisms
underlie physiological and pathological tau phosphoryl-
ation, circadian mechanisms may influence tau phos-
phorylation through their control over the daily rhythm
of core body temperature: a potent synchroniser of
peripheral clocks [62].
As for possible interactions between clocks and prion-
like propagation, there is only limited evidence. Dis-
turbed sleep is a feature of prion diseases [63], not least
fatal familial insomnia [64], and the absence of prion
protein in mice alters sleeping patterns [65]. As for
reciprocal effects, however, little is known, although
circadian expression of mRNA encoding prion protein
has been reported in rat brain [66]. In the absence of
knowledge as to how prion-like aggregates may transmit
pathology, it is difficult to divine circadian modulation of
the underlying mechanisms [1], other than to highlight
the strong circadian modulation of the expression of
synaptic vesicle-cycling proteins in brain that would
influence opportunities for exocytosis and endocytosis
that could underlie prion-like intercellular transmission
[25]. Nevertheless, an intriguing relationship between
sleep and Ab accumulation has been described in mice
transgenic for human mutant APP [67], with increased
levels of Ab in the interstitial fluid of the hippocampus
during wakefulness. A comparable daily cycle of Ab was
also noted in human CSF. In preclinical AD, sleep
quality deteriorated upon Ab deposition, before cogni-
tive symptoms [68], so did Ab plaques or sleep trouble
develop first? In mice transgenic for human mutant APP,
Ab deposition preceded sleep abnormalities and the
removal of plaques restored normal circadian rhythms
[69]. Conversely, sleep deprivation increased the levels
of Ab in the interstitial fluid of transgenic mice. These
findings suggest that sleep disturbances and Ab may
influence each other through a positive feedback loop.
Thus, the circadian sleep–wake cycle may contribute to
the pathogenesis of AD, and perhaps other neurodegen-
erative diseases.
Conclusion
It is well established that neurodegenerative diseases
compromise sleep and circadian clock functions. But,
whilst clock disturbance is not the primary cause of
neurodegeneration, it is clear that as the disease pro-
gresses and impairs clock/sleep functions, this will
enhance the brain’s susceptibility to the pathology and
aggravate its progression. Moreover, it is possible to
identify several points in disease progression where
exploitation of circadian principles could offer novel
therapeutic approaches. Thus, dealing with and manip-
ulating clock/sleep disturbances in neurodegenerative
disease is not solely a symptomatic treatment: rather it
may provide an important and novel avenue by which to
ameliorate progress of the disease.Current Opinion in Neurobiology 2013, 23:880–887
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